• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Bear mar­ket mauls an­oth­er small biotech as CEO, board mem­bers ex­it and ex­ecs bring out the axe, hunt deals

4 years ago
People

CRL ap­peal lands Arde­lyx an FDA ad­comm meet­ing for em­bat­tled CKD drug

4 years ago
R&D
FDA+

New York man­u­fac­tur­ing su­per­vi­sor gets 1-year sen­tence for steal­ing drugs for horse dop­ing scheme

4 years ago
Pharma
Manufacturing

Vi­vo Cap­i­tal pitch­es $60M to bring Ar­row­head­'s RNAi meds to Chi­na via joint ven­ture

4 years ago
Deals
China

Ax­olotls, chem­i­cal cock­tails, and a new route for stem cell ther­a­py — maybe

4 years ago
R&D
Discovery

Ax­some ex­pects mi­graine drug to be re­ject­ed as man­u­fac­tur­ing is­sues arise

4 years ago
Pharma
FDA+

Black Di­a­mond lays off 30% of its work­force and culls a drug from its 'Mas­terKey' chest

4 years ago
People
R&D

Fa­heem Has­nain ac­knowl­edges an­oth­er set­back for the Gos­samer pipeline, but in­vestors aren't pan­ick­ing

4 years ago
R&D

'Re­sults are un­am­bigu­ous': Eliem's lead pro­gram fails and share price halves be­fore open­ing bell

4 years ago
Startups
R&D

Serv­ing as a 'gate­way,' Cam­bridge ven­ture in­vestor clos­es $300M sec­ond fund

4 years ago
Financing

FDA warns small biotech Ocu­gen of po­ten­tial $10K fines for fail­ing to post tri­al re­sults

4 years ago
FDA+

Nkar­ta re­veals its first off-the-shelf NK cell da­ta, show­ing mul­ti­ple com­plete re­spons­es — shares soar

4 years ago
R&D
Cell/Gene Tx

Roche hit with an­oth­er key R&D set­back as oral SERD flops in breast can­cer

4 years ago
R&D

Af­ter 18 years in de­vel­op­ment, As­traZeneca’s CT­LA-4 an­ti­body gets the red car­pet treat­ment at the FDA

4 years ago
FDA+

New pa­per sheds fresh light on Tmu­ni­ty's high-pro­file CAR-T deaths

4 years ago
R&D
Cell/Gene Tx

End­points 20 un­der 40; Ver­dict on PI3K; Re­gen­eron goes dis­count shop­ping; $1.85B deal im­plodes; and more

4 years ago
Weekly

Phar­ma shells out more than $300K to broth­er of top Biden aide in 3 months

4 years ago
Pharma

Re­gen­eron co-founders slow down com­pen­sa­tion in 2021, net­ting just $13M com­bined af­ter $270M in 2020

4 years ago
People

With con­tract man­u­fac­tur­ing work in high de­mand, Nether­lands CD­MO lands new in­vest­ment

4 years ago
Pharma
Manufacturing

Sis­ters act: Catholic nuns call for more trans­paren­cy around the lob­by­ing of sev­er­al large phar­ma com­pa­nies

4 years ago
Pharma

Mod­er­na en­lists mom in­flu­encers and more in push to raise aware­ness of lit­tle known CMV

4 years ago
Pharma
Marketing

FDA plots mul­ti-day hear­ing to re­view 'dan­gling' ac­cel­er­at­ed ap­proval that drug­mak­er re­fus­es to pull

4 years ago
FDA+

Do pa­tients and physi­cians weigh drug risks dif­fer­ent­ly? FDA re­searchers plan to find out

4 years ago
Pharma
FDA+

Covid-19 roundup: WHO is­sues 'strong' rec­om­men­da­tion for Pfiz­er's Paxlovid but wants more price trans­paren­cy

4 years ago
Pharma
Coronavirus
First page Previous page 534535536537538539540 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times